Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx Cost-Effectiveness Beyond Medicare: Merck, AARP Plan Policy Meeting

Executive Summary

Merck and AARP are working with the Agency for Healthcare Research & Quality to organize a "stakeholders" meeting to discuss standards for cost-effectiveness research

You may also be interested in...



PhRMA Adopts Outcomes Research Policy; Set For Cost-Effectiveness Debate

Government-supported health outcomes research must recognize the benefits of multiple treatment options, the Pharmaceutical Research & Manufacturers of America's principles on outcomes research say

Cost-effectiveness research

Merck/AARP "invitation only" conference on cost-effectiveness/outcomes research is set for Jan. 28. The stakeholders meeting, which will include the Agency for Healthcare Research & Quality as a key participant, will attempt to develop a consensus on standards for research. Wharton Health Care Systems Department Chairman Mark Pauly, MD, will moderate the meeting (1"The Pink Sheet" Nov. 10, 2003, p. 3). The Pharmaceutical Research & Manufacturers of America is expected to discuss a position on outcomes research during its next board meeting, Jan. 15...

Cost-effectiveness research

Merck/AARP "invitation only" conference on cost-effectiveness/outcomes research is set for Jan. 28. The stakeholders meeting, which will include the Agency for Healthcare Research & Quality as a key participant, will attempt to develop a consensus on standards for research. Wharton Health Care Systems Department Chairman Mark Pauly, MD, will moderate the meeting (1"The Pink Sheet" Nov. 10, 2003, p. 3). The Pharmaceutical Research & Manufacturers of America is expected to discuss a position on outcomes research during its next board meeting, Jan. 15...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS042805

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel